246 related articles for article (PubMed ID: 12956767)
1. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
2. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
Kamal HM; Ahmed AS; Fawzy MS; Mohamed FA; Elbaz AA
Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
[TBL] [Abstract][Full Text] [Related]
3. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
4. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
Juhan-Vague I; Morange PE; Aubert H; Henry M; Aillaud MF; Alessi MC; Samnegård A; Hawe E; Yudkin J; Margaglione M; Di Minno G; Hamsten A; Humphries SE;
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):867-73. PubMed ID: 12006404
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
[TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
7. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Brouwers GJ; Leebeek FW; Tanck MW; Wouter Jukema J; Kluft C; de Maat MP
Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
[TBL] [Abstract][Full Text] [Related]
8. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Meltzer ME; Doggen CJ; de Groot PG; Meijers JC; Rosendaal FR; Lisman T
Haematologica; 2009 Jun; 94(6):811-8. PubMed ID: 19377074
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
10. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
11. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.
Segev A; Hegele RA; Lau HK; Sparkes JD; Teitel JM; Chisholm RJ; Strauss BH
Thromb Res; 2004; 114(2):137-41. PubMed ID: 15306156
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
Hamdy M; Shaheen IA; Khallaf M; Selim YMM
Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
[TBL] [Abstract][Full Text] [Related]
13. Association of TAFI gene polymorphisms with severity of coronary stenosis in stable coronary artery disease.
Rattanawan C; Komanasin N; Settasatian N; Settasatian C; Kukongviriyapan U; Intharapetch P; Senthong V
Thromb Res; 2018 Nov; 171():171-176. PubMed ID: 30321704
[TBL] [Abstract][Full Text] [Related]
14. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
Fawzy MS; Mohammed EA; Ahmed AS; Fakhr-Eldeen A
Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
[TBL] [Abstract][Full Text] [Related]
17. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases.
Naderi M; Alizadeh S; Kazemi A; Tabibian S; Zaker F; Bamedi T; Kashani Khatib Z; Dorgalaleh A
Hematology; 2015 Mar; 20(2):112-8. PubMed ID: 25001244
[TBL] [Abstract][Full Text] [Related]
19. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Fernandez-Cadenas I; Alvarez-Sabin J; Ribo M; Rubiera M; Mendioroz M; Molina CA; Rosell A; Montaner J
J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
[TBL] [Abstract][Full Text] [Related]
20. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
